EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial

Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin, Florent Amatore, Julie S Deutsch, Rodrigo X Das Neves, Richard R Rodrigues, John A McCulloch, Hong Wang, Douglas J Hartman und 41 weitere

Cancer Cell · 2024-11 · 42 (11) · 1898-1918.e12

DOI: 10.1016/j.ccell.2024.10.007 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2024-11. Verfasst von Diwakar Davar und 52 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillm…. Hauptthemen laut MEDLINE: Melanoma, Nivolumab, Neoadjuvant Therapy. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR was associated with necrosis, and melanophagocytosis with increased CD8+ tumor-infiltrating lymphocytes and plasmacytoid dendritic cells (pDCs) in the tumor microenvironment, and increased frequencies of Ki67+CD8+ T cells peripherally. MPRs had an enriched pre-treatment gene signature of myeloid cells, and response to therapy was associated with gene signatures of immune cells, pDCs, phagocytosis, and macrophage activation. MPRs gut microbiota were enriched for Gram-negative bacteria belonging to the Bacteroidaceae and Enterobacteriaceae families and the small subgroup of Gram-negative Firmicutes. Our findings support that combined vidutolimod and nivolumab stimulates a broad anti-tumor immune response and is associated with distinct baseline myeloid gene signature and gut microbiota. ClinicalTrials.gov identifier: NCT03618641.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNivolumabNeoadjuvant TherapyHumansMaleFemaleMiddle AgedProspective StudiesAgedAntineoplastic Combined Chemotherapy ProtocolsAdultLymphocytes, Tumor-InfiltratingTumor MicroenvironmentGastrointestinal MicrobiomeImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

ICIPD-1TLR9immunotherapyinnate agonistmacrophagemelanomaneoadjuvantpDCvidutolimod

Substanzen

NivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Computational and…
  • Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
  • University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA.
  • Division of Dermatopathology, Johns Hopkins University, Baltimore, MD, USA.

Förderung

  • NCI NIH HHS
  • NIH HHS

Zitieren

APA

Davar, D., Morrison, R. M., Dzutsev, A. K., Karunamurthy, A., Chauvin, J. M., Amatore, F., Deutsch, J. S., Das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., Wang, H., Hartman, D. J., Badger, J. H., Fernandes, M. R., Bai, Y., Sun, J., Cole, A. M., Aggarwal, P., Fang, J. R., …, & Zarour, H. M. (2024). Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell, 42(11), 1898-1918.e12. https://doi.org/10.1016/j.ccell.2024.10.007

Vancouver

Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, et al. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024;42(11):1898-1918.e12. doi:10.1016/j.ccell.2024.10.007

BibTeX
@article{Davar2024,
  author = {Davar, Diwakar and Morrison, Robert M and Dzutsev, Amiran K and Karunamurthy, Arivarasan and Chauvin, Joe-Marc and Amatore, Florent and Deutsch, Julie S and Das Neves, Rodrigo X and Rodrigues, Richard R and McCulloch, John A and Wang, Hong and Hartman, Douglas J and Badger, Jonathan H and Fernandes, Miriam R and Bai, Yulong and Sun, Jie and Cole, Alicia M and Aggarwal, Poonam and Fang, Jennifer R and Deitrick, Christopher and Bao, Riyue and Duvvuri, Umamaheswar and Sridharan, Shaum S and Kim, Seungwon W and A Choudry, Haroon and Holtzman, Matthew P and Pingpank, James F and O'Toole, James Patrick and DeBlasio, Richelle and Jin, Yang and Ding, Quanquan and Gao, Wentao and Groetsch, Christopher and Pagliano, Ornella and Rose, Amy and Urban, Corey and Singh, Jagjit and Divarkar, Prajan and Mauro, David and Bobilev, Dmitri and Wooldridge, James and Krieg, Arthur M and Fury, Matthew G and Whiteaker, Jeffrey R and Zhao, Lei and Paulovich, Amanda G and Najjar, Yana G and Luke, Jason J and Kirkwood, John M and Taube, Janis M and Park, Hyun Jung and Trinchieri, Giorgio and Zarour, Hassane M},
  title = {Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {11},
  pages = {1898--1918.e12},
  doi = {10.1016/j.ccell.2024.10.007}
}
Kostenlos starten →